

Patient ID SA00143837	Patient Name SAMPLEREPORT, TESTINGPATIENT	Birth Date 1987-12-28	Gender F	Age 33
Order Number SA00143837	Client Order Number SA00143837	Ordering Physician CLIENT,CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 05 Apr 2021 00:00		

Rivaroxaban, Anti-Xa, P

Result Name	Value	Unit	Reference Value	Performing Site
  Rivaroxaban, Anti-Xa, P	8	ng/mL	<4	1 MCR

Interpretation

Therapeutic reference ranges have not been established. Median (5th-95th percentile) peak and trough levels observed in clinical trials are shown.

VTE Prevention after total hip replacement surgery:

Peak levels (2–4 hrs post dose):
10 mg (once daily): 125 (91–196) ng/mL

Trough levels (20–28 hrs post dose):
10 mg (once daily): 9 (1–38) ng/mL

Deep vein thrombosis continued treatment:

Peak levels (2–4 hrs post dose):
20 mg (once daily): 270 (189–419) ng/mL

Trough levels (20–28 hrs post dose):
20 mg (once daily): 26 (6–87) ng/mL

Non-valvular atrial fib (CR clearance $\geq$ 50 mL/min):

Peak levels (2–4 hrs post dose):
20 mg (once daily): 249 (184–343) ng/mL

MCR

Trough levels (20–28 hrs post dose):
20 mg (once daily): 44 (12–137) ng/mL

Non-valvular atrial fib (CR clearance 30–49 mL/min):

Peak levels (2–4 hrs post dose):
15 mg (once daily): 229 (178–313) ng/mL

Trough levels (20–28 hrs post dose):
15 mg (once daily): 57 (18–136) ng/mL

Acute coronary syndrome, secondary prevention:

Peak levels (2–4 hrs post dose):
2.5 mg (twice daily): 46 (28–70) ng/mL

Trough levels (20–28 hrs post dose):
2.5 mg (twice daily): 17 (6–37) ng/mL

Cautions

This assay is not indicated for monitoring low molecular weight heparin (LMWH) or unfractionated heparin (UFH). Presence of UFH and LMWH will falsely elevate rivaroxaban anti-Xa levels.

MCR

Received: 05 Apr 2021 12:40

Reported: 05 Apr 2021 12:41

Laboratory Notes

- 1** This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292

Report Status: Final